---
title: "Fulcrum Therapeutics initial beneficial ownership filing shows Kevin Tang as 10% owner"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292826467.md"
description: "Fulcrum Therapeutics filed a Form 3 with the SEC, disclosing that Kevin Tang and Tang Capital Management hold indirect beneficial ownership of 6,663,383 shares, representing approximately 10% of the company's common stock. The event date is July 13, 2026, and the filing was signed on July 15, 2026."
datetime: "2026-07-15T23:50:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292826467.md)
  - [en](https://longbridge.com/en/news/292826467.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292826467.md)
---

# Fulcrum Therapeutics initial beneficial ownership filing shows Kevin Tang as 10% owner

-   Fulcrum Therapeutics Form 3 filed for Kevin Tang and Tang Capital Management, listed as 10% owners. \* Disclosure shows indirect beneficial ownership of 6,663,383 shares of common stock. \* Event date July 13, 2026; filing signed July 15, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulcrum Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178579-26-000013), on July 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [FULC.US](https://longbridge.com/en/quote/FULC.US.md)

## Related News & Research

- [Fulcrum CFO Alan Musso takes over as principal accounting officer after Tourangeau exit](https://longbridge.com/en/news/295409058.md)
- [Fulcrum Therapeutics 10% owner Kevin Tang acquires $594,132 of common shares](https://longbridge.com/en/news/293268525.md)
- [Fulcrum Therapeutics director Alan Ezekowitz disposes of 18,000 common shares for $65,614](https://longbridge.com/en/news/291330614.md)
- [Fulcrum Therapeutics Approves Restructuring Plan After Discontinuing Pociredir For Sickle Cell Disease](https://longbridge.com/en/news/288767758.md)
- [Fulcrum Therapeutics Plunges After Pociredir Program Halt In Sickle Cell Disease](https://longbridge.com/en/news/288376467.md)